Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer
Background Mesothelin is overexpressed in many solid tumors, and recent studies have shown that mesothelin expression is associated with poor outcomes in several malignant tumors and may play a role in cancer progression. Clinical trials of mesothelin‐targeted immunotherapies are currently under way...
Saved in:
Published in | The oncologist (Dayton, Ohio) Vol. 24; no. 11; pp. e1108 - e1114 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.11.2019
|
Subjects | |
Online Access | Get full text |
ISSN | 1083-7159 1549-490X 1549-490X |
DOI | 10.1634/theoncologist.2018-0896 |
Cover
Abstract | Background
Mesothelin is overexpressed in many solid tumors, and recent studies have shown that mesothelin expression is associated with poor outcomes in several malignant tumors and may play a role in cancer progression. Clinical trials of mesothelin‐targeted immunotherapies are currently under way, but the correlation between mesothelin expression and gastric cancer prognosis is still unclear.
Subjects, Materials, and Methods
Mesothelin expression in tumor cells was evaluated immunohistochemically in 958 patients with advanced gastric cancer and interpreted according to the intensity and extent of staining. Samples were scored from 0 to 2, with high expression defined as a score of 2. Clinicopathological factors, overall survival (OS), recurrence‐free survival (RFS), and sites of initial recurrence, including peritoneal recurrence, were evaluated. Staging was performed according to the American Joint Committee on Cancer 7th edition.
Results
High mesothelin expression was observed in 49.7% of patients and significantly associated with high pathologic T (p = .021) and peritoneal recurrence (p = .018). Multivariate survival analysis showed that high mesothelin expression was independently associated with poor RFS (p = .001), OS (p = .001), and peritoneal recurrence (p = .002) in addition to stage, lymphovascular invasion, and Lauren classification. In a subgroup analysis of peritoneal recurrence, high mesothelin expression was also an independent prognostic factor in stage III (p = .013) and diffuse/mixed type gastric cancer (p = .010).
Conclusion
High mesothelin expression is correlated with poor outcomes. In addition, mesothelin expression, Lauren classification, and stage are meaningful predictive factors for peritoneal recurrence. Moreover, mesothelin was a significant predictor of a high risk of peritoneal recurrence in patients with stage III gastric cancer.
Implications for Practice
This study demonstrates that high mesothelin expression correlates with poor outcomes and is a significant predictor of peritoneal recurrence in patients with stage III gastric cancer. This study provides instrumental evidence for designing anti‐mesothelin antibody‐drug conjugate clinical trials in patients with diffuse‐type gastric cancer to reduce their high risk of peritoneal carcinomatosis.
摘要
背景。间皮素在很多实体肿瘤中会过度表达,近期研究表明,间皮素表达与若干恶性肿瘤的预后不良有关,并且可能在癌症进展过程中起到一定的作用。尽管目前正在进行以间皮素为靶标的免疫疗法的临床试验,但是间皮素表达与胃癌预后之间的相关性尚不明确。
对象、材料和方法。我们对 958 例晚期胃癌患者的癌细胞间皮素表达进行了免疫组织化学评估,并根据染色的强度和程度进行了解释。样本得分为 0 到 2 分,而 2 分则定义为高表达。我们还评估了临床病理因素、总生存期 (OS)、无复发生存期 (RFS) 和初次复发部位,包括腹膜复发。根据美国癌症联合委员会第 7 版进行分期。
结果。在 49.7% 的患者中观察到间皮素高表达,且该间皮素高表达与较高的病理性 T (p = 0.021) 以及腹膜复发 (p = 0.018) 显著相关。多因素生存分析表明,除了分期、淋巴血管浸润和 Lauren 分类之外,间皮素高表达还与不良 RFS (p = 0.001)、OS (p = 0.001) 以及腹膜复发 (p = 0.002) 等因素独立相关。腹膜复发的亚组分析表明,间皮素高表达也是 III 期 (p = 0.013) 和弥漫型/混合型胃癌 (p = 0.010) 的独立预后因素。
结论。间皮素高表达与预后不良相关。此外,间皮素表达、Lauren 分类和分期对腹膜复发而言是意义重大的预测因素。而且,间皮素是 III 期胃癌患者腹膜复发高风险的重要预测因素。
实践意义:本研究表明,间皮素高表达与预后不良相关,并且是 III 期胃癌患者腹膜复发的重要预测因素。本研究为设计弥漫型胃癌患者的抗‐间皮素抗体‐药物偶联物临床试验,从而降低腹膜转移的高风险提供了有效证据。
This article examines mesothelin expression with a focus on its potential as a predictive biomarker of peritoneal recurrence after curative surgery and its prognostic significance and association with clinicopathological factors in gastric cancer. |
---|---|
AbstractList | This article examines mesothelin expression with a focus on its potential as a predictive biomarker of peritoneal recurrence after curative surgery and its prognostic significance and association with clinicopathological factors in gastric cancer. Background Mesothelin is overexpressed in many solid tumors, and recent studies have shown that mesothelin expression is associated with poor outcomes in several malignant tumors and may play a role in cancer progression. Clinical trials of mesothelin‐targeted immunotherapies are currently under way, but the correlation between mesothelin expression and gastric cancer prognosis is still unclear. Subjects, Materials, and Methods Mesothelin expression in tumor cells was evaluated immunohistochemically in 958 patients with advanced gastric cancer and interpreted according to the intensity and extent of staining. Samples were scored from 0 to 2, with high expression defined as a score of 2. Clinicopathological factors, overall survival (OS), recurrence‐free survival (RFS), and sites of initial recurrence, including peritoneal recurrence, were evaluated. Staging was performed according to the American Joint Committee on Cancer 7th edition. Results High mesothelin expression was observed in 49.7% of patients and significantly associated with high pathologic T (p = .021) and peritoneal recurrence (p = .018). Multivariate survival analysis showed that high mesothelin expression was independently associated with poor RFS (p = .001), OS (p = .001), and peritoneal recurrence (p = .002) in addition to stage, lymphovascular invasion, and Lauren classification. In a subgroup analysis of peritoneal recurrence, high mesothelin expression was also an independent prognostic factor in stage III (p = .013) and diffuse/mixed type gastric cancer (p = .010). Conclusion High mesothelin expression is correlated with poor outcomes. In addition, mesothelin expression, Lauren classification, and stage are meaningful predictive factors for peritoneal recurrence. Moreover, mesothelin was a significant predictor of a high risk of peritoneal recurrence in patients with stage III gastric cancer. Implications for Practice This study demonstrates that high mesothelin expression correlates with poor outcomes and is a significant predictor of peritoneal recurrence in patients with stage III gastric cancer. This study provides instrumental evidence for designing anti‐mesothelin antibody‐drug conjugate clinical trials in patients with diffuse‐type gastric cancer to reduce their high risk of peritoneal carcinomatosis. 摘要 背景。间皮素在很多实体肿瘤中会过度表达,近期研究表明,间皮素表达与若干恶性肿瘤的预后不良有关,并且可能在癌症进展过程中起到一定的作用。尽管目前正在进行以间皮素为靶标的免疫疗法的临床试验,但是间皮素表达与胃癌预后之间的相关性尚不明确。 对象、材料和方法。我们对 958 例晚期胃癌患者的癌细胞间皮素表达进行了免疫组织化学评估,并根据染色的强度和程度进行了解释。样本得分为 0 到 2 分,而 2 分则定义为高表达。我们还评估了临床病理因素、总生存期 (OS)、无复发生存期 (RFS) 和初次复发部位,包括腹膜复发。根据美国癌症联合委员会第 7 版进行分期。 结果。在 49.7% 的患者中观察到间皮素高表达,且该间皮素高表达与较高的病理性 T (p = 0.021) 以及腹膜复发 (p = 0.018) 显著相关。多因素生存分析表明,除了分期、淋巴血管浸润和 Lauren 分类之外,间皮素高表达还与不良 RFS (p = 0.001)、OS (p = 0.001) 以及腹膜复发 (p = 0.002) 等因素独立相关。腹膜复发的亚组分析表明,间皮素高表达也是 III 期 (p = 0.013) 和弥漫型/混合型胃癌 (p = 0.010) 的独立预后因素。 结论。间皮素高表达与预后不良相关。此外,间皮素表达、Lauren 分类和分期对腹膜复发而言是意义重大的预测因素。而且,间皮素是 III 期胃癌患者腹膜复发高风险的重要预测因素。 实践意义:本研究表明,间皮素高表达与预后不良相关,并且是 III 期胃癌患者腹膜复发的重要预测因素。本研究为设计弥漫型胃癌患者的抗‐间皮素抗体‐药物偶联物临床试验,从而降低腹膜转移的高风险提供了有效证据。 This article examines mesothelin expression with a focus on its potential as a predictive biomarker of peritoneal recurrence after curative surgery and its prognostic significance and association with clinicopathological factors in gastric cancer. Mesothelin is overexpressed in many solid tumors, and recent studies have shown that mesothelin expression is associated with poor outcomes in several malignant tumors and may play a role in cancer progression. Clinical trials of mesothelin-targeted immunotherapies are currently under way, but the correlation between mesothelin expression and gastric cancer prognosis is still unclear. Mesothelin expression in tumor cells was evaluated immunohistochemically in 958 patients with advanced gastric cancer and interpreted according to the intensity and extent of staining. Samples were scored from 0 to 2, with high expression defined as a score of 2. Clinicopathological factors, overall survival (OS), recurrence-free survival (RFS), and sites of initial recurrence, including peritoneal recurrence, were evaluated. Staging was performed according to the American Joint Committee on Cancer 7th edition. High mesothelin expression was observed in 49.7% of patients and significantly associated with high pathologic T ( = .021) and peritoneal recurrence ( = .018). Multivariate survival analysis showed that high mesothelin expression was independently associated with poor RFS ( = .001), OS ( = .001), and peritoneal recurrence ( = .002) in addition to stage, lymphovascular invasion, and Lauren classification. In a subgroup analysis of peritoneal recurrence, high mesothelin expression was also an independent prognostic factor in stage III ( = .013) and diffuse/mixed type gastric cancer ( = .010). High mesothelin expression is correlated with poor outcomes. In addition, mesothelin expression, Lauren classification, and stage are meaningful predictive factors for peritoneal recurrence. Moreover, mesothelin was a significant predictor of a high risk of peritoneal recurrence in patients with stage III gastric cancer. This study demonstrates that high mesothelin expression correlates with poor outcomes and is a significant predictor of peritoneal recurrence in patients with stage III gastric cancer. This study provides instrumental evidence for designing anti-mesothelin antibody-drug conjugate clinical trials in patients with diffuse-type gastric cancer to reduce their high risk of peritoneal carcinomatosis. Mesothelin is overexpressed in many solid tumors, and recent studies have shown that mesothelin expression is associated with poor outcomes in several malignant tumors and may play a role in cancer progression. Clinical trials of mesothelin-targeted immunotherapies are currently under way, but the correlation between mesothelin expression and gastric cancer prognosis is still unclear.BACKGROUNDMesothelin is overexpressed in many solid tumors, and recent studies have shown that mesothelin expression is associated with poor outcomes in several malignant tumors and may play a role in cancer progression. Clinical trials of mesothelin-targeted immunotherapies are currently under way, but the correlation between mesothelin expression and gastric cancer prognosis is still unclear.Mesothelin expression in tumor cells was evaluated immunohistochemically in 958 patients with advanced gastric cancer and interpreted according to the intensity and extent of staining. Samples were scored from 0 to 2, with high expression defined as a score of 2. Clinicopathological factors, overall survival (OS), recurrence-free survival (RFS), and sites of initial recurrence, including peritoneal recurrence, were evaluated. Staging was performed according to the American Joint Committee on Cancer 7th edition.SUBJECTS, MATERIALS, AND METHODSMesothelin expression in tumor cells was evaluated immunohistochemically in 958 patients with advanced gastric cancer and interpreted according to the intensity and extent of staining. Samples were scored from 0 to 2, with high expression defined as a score of 2. Clinicopathological factors, overall survival (OS), recurrence-free survival (RFS), and sites of initial recurrence, including peritoneal recurrence, were evaluated. Staging was performed according to the American Joint Committee on Cancer 7th edition.High mesothelin expression was observed in 49.7% of patients and significantly associated with high pathologic T (p = .021) and peritoneal recurrence (p = .018). Multivariate survival analysis showed that high mesothelin expression was independently associated with poor RFS (p = .001), OS (p = .001), and peritoneal recurrence (p = .002) in addition to stage, lymphovascular invasion, and Lauren classification. In a subgroup analysis of peritoneal recurrence, high mesothelin expression was also an independent prognostic factor in stage III (p = .013) and diffuse/mixed type gastric cancer (p = .010).RESULTSHigh mesothelin expression was observed in 49.7% of patients and significantly associated with high pathologic T (p = .021) and peritoneal recurrence (p = .018). Multivariate survival analysis showed that high mesothelin expression was independently associated with poor RFS (p = .001), OS (p = .001), and peritoneal recurrence (p = .002) in addition to stage, lymphovascular invasion, and Lauren classification. In a subgroup analysis of peritoneal recurrence, high mesothelin expression was also an independent prognostic factor in stage III (p = .013) and diffuse/mixed type gastric cancer (p = .010).High mesothelin expression is correlated with poor outcomes. In addition, mesothelin expression, Lauren classification, and stage are meaningful predictive factors for peritoneal recurrence. Moreover, mesothelin was a significant predictor of a high risk of peritoneal recurrence in patients with stage III gastric cancer.CONCLUSIONHigh mesothelin expression is correlated with poor outcomes. In addition, mesothelin expression, Lauren classification, and stage are meaningful predictive factors for peritoneal recurrence. Moreover, mesothelin was a significant predictor of a high risk of peritoneal recurrence in patients with stage III gastric cancer.This study demonstrates that high mesothelin expression correlates with poor outcomes and is a significant predictor of peritoneal recurrence in patients with stage III gastric cancer. This study provides instrumental evidence for designing anti-mesothelin antibody-drug conjugate clinical trials in patients with diffuse-type gastric cancer to reduce their high risk of peritoneal carcinomatosis.IMPLICATIONS FOR PRACTICEThis study demonstrates that high mesothelin expression correlates with poor outcomes and is a significant predictor of peritoneal recurrence in patients with stage III gastric cancer. This study provides instrumental evidence for designing anti-mesothelin antibody-drug conjugate clinical trials in patients with diffuse-type gastric cancer to reduce their high risk of peritoneal carcinomatosis. |
Author | Kim, Hyunki Choi, Yoon Young Choi, Hye Jin Chung, Hyun Cheol Nam, Chung Mo Shin, Su‐Jin Jung, Min Kyu Rha, Sun Young Park, Sejung Kim, Min Hwan |
Author_xml | – sequence: 1 givenname: Su‐Jin orcidid: 0000-0001-9114-8438 surname: Shin fullname: Shin, Su‐Jin organization: Department of Pathology, College of Medicine, Hanyang University – sequence: 2 givenname: Sejung surname: Park fullname: Park, Sejung organization: Department of Biostatistics, Yonsei University College of Medicine – sequence: 3 givenname: Min Hwan surname: Kim fullname: Kim, Min Hwan organization: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine – sequence: 4 givenname: Chung Mo surname: Nam fullname: Nam, Chung Mo organization: Department of Preventive Medicine, Yonsei University College of Medicine – sequence: 5 givenname: Hyunki surname: Kim fullname: Kim, Hyunki organization: Department of Pathology, Yonsei University College of Medicine – sequence: 6 givenname: Yoon Young surname: Choi fullname: Choi, Yoon Young organization: Department of Surgery, Yonsei University College of Medicine – sequence: 7 givenname: Min Kyu surname: Jung fullname: Jung, Min Kyu organization: Cancer Metastasis Research Center, Song Dang Institute for Cancer Research, Yonsei University College of Medicine – sequence: 8 givenname: Hye Jin surname: Choi fullname: Choi, Hye Jin organization: Cancer Metastasis Research Center, Song Dang Institute for Cancer Research, Yonsei University College of Medicine – sequence: 9 givenname: Sun Young surname: Rha fullname: Rha, Sun Young organization: Cancer Metastasis Research Center, Song Dang Institute for Cancer Research, Yonsei University College of Medicine – sequence: 10 givenname: Hyun Cheol orcidid: 0000-0002-0920-9471 surname: Chung fullname: Chung, Hyun Cheol email: unchung8@yuhs.ac organization: Cancer Metastasis Research Center, Song Dang Institute for Cancer Research, Yonsei University College of Medicine |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31015316$$D View this record in MEDLINE/PubMed |
BookMark | eNqVUdtuFCEYJqbGHvQVlEtvpsIwB7jQxEzaOkl1Gw-Jd4Rh_t1iWNgCs3XfXsath3pVLwg_-U7wcYwOnHeA0AtKTmnDqlfpGrzT3vqViem0JJQXhIvmETqidSWKSpCvB3kmnBUtrcUhOo7xGyF5ZOUTdMhoHhltjtD2PUSf3axx-Oz7JkCMxjvcR6zwVYDR6GS2gM-VTj7gZV5XEEzKt1EWfwQ9hQBOA87ybgpqJttdBiLoBCP-lNQKcN_3-ELFFIzGncr08BQ9Xiob4dndfoK-nJ997t4Vl4uLvnt7WeiacVoIpglhLeNNJRSwpq5H0AJGzdrlwBVlnCx1PikYS6q04JTrjBE9DHTgtGQniO99J7dRu1tlrdwEs1ZhJymRc5XyXpVyrlLOVWbpm710Mw3rHAkuBfVH7pWR9xFnruXKb2XDc7U_s1_eGQR_M0E2X5uowVrlwE9RliVlgraVoJn6_O-s3yG__ikTXu8JOvgYAyylNim37edoYx_wmPYf_X_XcGss7B4qk4sP3YKWoqbsB0hA2fk |
CitedBy_id | crossref_primary_10_3390_biomedicines9040397 crossref_primary_10_1016_j_ajpath_2024_07_009 crossref_primary_10_1158_1541_7786_MCR_19_0688 crossref_primary_10_1002_ags3_12565 crossref_primary_10_1016_j_adcanc_2023_100098 crossref_primary_10_1038_s41434_023_00388_z crossref_primary_10_3390_cancers12082236 crossref_primary_10_1007_s12672_024_01159_x crossref_primary_10_3389_fonc_2021_781800 crossref_primary_10_3389_fvets_2024_1436621 crossref_primary_10_4251_wjgo_v14_i1_90 crossref_primary_10_1200_JCO_21_02745 crossref_primary_10_3390_jcm9061894 crossref_primary_10_1159_000526333 crossref_primary_10_1007_s11912_023_01367_8 crossref_primary_10_2217_imt_2021_0285 crossref_primary_10_1007_s10555_020_09924_4 crossref_primary_10_3390_biom10070973 |
Cites_doi | 10.1158/1055-9965.EPI-11-0993 10.2174/1871520611313020014 10.1111/j.0006-341X.2005.030814.x 10.1128/MCB.20.8.2902-2906.2000 10.1007/s13277-015-3304-7 10.1186/s12957-016-1042-y 10.1016/S1470-2045(14)70473-5 10.1038/bjc.2012.235 10.1002/jso.22024 10.1158/0008-5472.CAN-14-0337 10.1007/s00268-010-0573-6 10.1097/SLA.0000000000002040 10.18632/oncotarget.4461 10.1007/PL00011698 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 10.1002/sim.6428 10.3322/caac.21262 10.1016/S0140-6736(11)61873-4 10.1371/journal.pone.0114900 10.1016/j.ejso.2010.09.006 10.1111/apm.1965.64.1.31 10.1158/1078-0432.CCR-13-1862 10.1038/srep01870 10.1158/1078-0432.CCR-11-2614 10.1038/nature13480 10.1002/cncr.22317 10.3748/wjg.v22.i30.6829 10.1158/2159-8290.CD-15-0583 10.1089/gtmb.2017.0060 10.1074/jbc.M312372200 |
ContentType | Journal Article |
Copyright | AlphaMed Press 2019 AlphaMed Press 2019. |
Copyright_xml | – notice: AlphaMed Press 2019 – notice: AlphaMed Press 2019. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ADTOC UNPAY |
DOI | 10.1634/theoncologist.2018-0896 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1549-490X |
EndPage | e1114 |
ExternalDocumentID | 10.1634/theoncologist.2018-0896 PMC6853112 31015316 10_1634_theoncologist_2018_0896 ONCO12951 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- 0R~ 123 18M 1OC 24P 2WC 36B 4.4 53G 5VS AAPXW AAVAP AAWTL AAZKR ABEJV ABPTD ABXVV ACXQS ADBBV ADXAS AEGXH AENEX AJAOE ALMA_UNASSIGNED_HOLDINGS AMNDL AOIJS BAWUL BFHJK CS3 DCZOG DIK DU5 E3Z EBD EBS EJD EMB EMOBN F5P FRP GROUPED_DOAJ GX1 H13 HYE HZ~ IAO IHR INH ITC LUTES LYRES O9- OK1 P2P P2W RAO RHF RHI ROL ROX RPM SUPJJ SV3 TOX TR2 UDS W2D W8F WIN WOHZO WOQ WOW XSB ZZTAW AAFWJ AAMMB AAYXX ABGNP AEFGJ AFPKN AGXDD AIDQK AIDYY CITATION OVT 7X7 88E 8FI 8FJ ABUWG AFKRA BENPR CCPQU CGR CUY CVF ECM EIF FYUFA HMCUK M1P NPM PHGZM PHGZT PIMPY PJZUB PPXIY PSQYO UKHRP 7X8 5PM ADTOC UNPAY |
ID | FETCH-LOGICAL-c5381-93c003738649ae3655dec9edc37fb8a1380fcdc3aed21ac9818cc370cbb1b8123 |
IEDL.DBID | UNPAY |
ISSN | 1083-7159 1549-490X |
IngestDate | Tue Aug 19 17:23:44 EDT 2025 Thu Aug 21 18:03:26 EDT 2025 Wed Oct 01 12:55:13 EDT 2025 Mon Jul 21 05:56:58 EDT 2025 Thu Apr 24 22:55:48 EDT 2025 Wed Oct 01 02:01:44 EDT 2025 Wed Jan 22 16:38:56 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | Mesothelin Stomach cancer Survival Peritoneal recurrence Prediction |
Language | English |
License | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model AlphaMed Press 2019. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5381-93c003738649ae3655dec9edc37fb8a1380fcdc3aed21ac9818cc370cbb1b8123 |
Notes | . Disclosures of potential conflicts of interest may be found at the end of this article ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Disclosures of potential conflicts of interest may be found at the end of this article. |
ORCID | 0000-0002-0920-9471 0000-0001-9114-8438 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1634/theoncologist.2018-0896 |
PMID | 31015316 |
PQID | 2213917491 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | unpaywall_primary_10_1634_theoncologist_2018_0896 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6853112 proquest_miscellaneous_2213917491 pubmed_primary_31015316 crossref_citationtrail_10_1634_theoncologist_2018_0896 crossref_primary_10_1634_theoncologist_2018_0896 wiley_primary_10_1634_theoncologist_2018_0896_ONCO12951 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | November 2019 |
PublicationDateYYYYMMDD | 2019-11-01 |
PublicationDate_xml | – month: 11 year: 2019 text: November 2019 |
PublicationDecade | 2010 |
PublicationPlace | Hoboken, USA |
PublicationPlace_xml | – name: Hoboken, USA – name: England |
PublicationTitle | The oncologist (Dayton, Ohio) |
PublicationTitleAlternate | Oncologist |
PublicationYear | 2019 |
Publisher | John Wiley & Sons, Inc |
Publisher_xml | – name: John Wiley & Sons, Inc |
References | 2010; 34 2015; 34 2015; 36 2014; 513 2013; 3 2015; 6 2010; 36 2010 2000; 3 2018; 267 2017; 21 2000; 20 2012; 18 2005; 61 2012; 105 1996; 15 2016; 14 2012; 107 2016; 34 2014; 20 1992; 52 2016; 6 1965; 64 2004; 279 2013; 13 2015; 65 2014; 15 2014; 9 2014; 74 2012; 379 2006; 107 2012; 21 2016; 22 Torre (2021122508114463600_onco12951-bib-0001) 2015; 65 Yonemura (2021122508114463600_onco12951-bib-0030) 2000; 3 Lauren (2021122508114463600_onco12951-bib-0020) 1965; 64 Demler (2021122508114463600_onco12951-bib-0019) 2015; 34 Tang (2021122508114463600_onco12951-bib-0010) 2013; 13 Pastan (2021122508114463600_onco12951-bib-0033) 2014; 74 Bilici (2021122508114463600_onco12951-bib-0006) 2015; 36 Yonemura (2021122508114463600_onco12951-bib-0007) 2010; 36 Noh (2021122508114463600_onco12951-bib-0004) 2014; 15 Heagerty (2021122508114463600_onco12951-bib-0018) 2005; 61 Rizk (2021122508114463600_onco12951-bib-0026) 2012; 21 Cancer Genome Atlas Research Network (2021122508114463600_onco12951-bib-0021) 2014; 513 Kanda (2021122508114463600_onco12951-bib-0022) 2016; 22 Servais (2021122508114463600_onco12951-bib-0012) 2012; 18 Lee (2021122508114463600_onco12951-bib-0023) 2018; 267 Chen (2021122508114463600_onco12951-bib-0028) 2013; 3 Zeng (2021122508114463600_onco12951-bib-0009) 2017; 21 Rump (2021122508114463600_onco12951-bib-0029) 2004; 279 Baba (2021122508114463600_onco12951-bib-0015) 2012; 105 Rohatgi (2021122508114463600_onco12951-bib-0003) 2006; 107 Bera (2021122508114463600_onco12951-bib-0024) 2000; 20 Lamberts (2021122508114463600_onco12951-bib-0032) 2015; 6 Blumenschein (2021122508114463600_onco12951-bib-0014) 2016; 34 Morello (2021122508114463600_onco12951-bib-0011) 2016; 6 Tozbikian (2021122508114463600_onco12951-bib-0027) 2014; 9 Edge (2021122508114463600_onco12951-bib-0016) 2010 Harrell (2021122508114463600_onco12951-bib-0017) 1996; 15 Kachala (2021122508114463600_onco12951-bib-0025) 2014; 20 Bang (2021122508114463600_onco12951-bib-0002) 2012; 379 Chang (2021122508114463600_onco12951-bib-0031) 1992; 52 Einama (2021122508114463600_onco12951-bib-0013) 2012; 107 Liu (2021122508114463600_onco12951-bib-0005) 2016; 14 Ito (2021122508114463600_onco12951-bib-0008) 2010; 34 |
References_xml | – volume: 379 start-page: 315 year: 2012 end-page: 321 article-title: Adjuvant capecitabine and oxaliplatin for gastric cancer after d2 gastrectomy (classic): A phase 3 open‐label, randomised controlled trial publication-title: Lancet – volume: 3 start-page: 63 year: 2000 end-page: 70 article-title: Role of MMP‐7 in the formation of peritoneal dissemination in gastric cancer publication-title: Gastric Cancer – volume: 61 start-page: 92 year: 2005 end-page: 105 article-title: Survival model predictive accuracy and ROC curves publication-title: Biometrics – volume: 36 start-page: 6191 year: 2015 end-page: 6199 article-title: Prognostic significance of the recurrence pattern and risk factors for recurrence in patients with proximal gastric cancer who underwent curative gastrectomy publication-title: Tumour Biol – volume: 65 start-page: 87 year: 2015 end-page: 108 article-title: Global cancer statistics, 2012 publication-title: CA Cancer J Clin – volume: 21 start-page: 482 year: 2012 end-page: 486 article-title: Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma publication-title: Cancer Epidemiol Biomarkers Prev – volume: 3 start-page: 1870 year: 2013 article-title: Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP‐7 activation publication-title: Sci Rep – volume: 52 start-page: 181 year: 1992 end-page: 186 article-title: Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium publication-title: Cancer Res – volume: 34 issue: suppl 15 year: 2016 article-title: Phase I study of anti‐mesothelin antibody drug conjugate anetumab ravtansine (AR) publication-title: J Clin Oncol – volume: 22 start-page: 6829 year: 2016 end-page: 6840 article-title: Molecular mechanisms of peritoneal dissemination in gastric cancer publication-title: World J Gastroenterol – volume: 18 start-page: 2478 year: 2012 end-page: 2489 article-title: Mesothelin overexpression promotes mesothelioma cell invasion and MMP‐9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients publication-title: Clin Cancer Res – volume: 74 start-page: 2907 year: 2014 end-page: 2912 article-title: Discovery of mesothelin and exploiting it as a target for immunotherapy publication-title: Cancer Res – volume: 6 start-page: 28164 year: 2015 end-page: 28172 article-title: Functional genomic mrna profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types publication-title: Oncotarget – volume: 36 start-page: 1131 year: 2010 end-page: 1138 article-title: Surgical treatment for peritoneal carcinomatosis from gastric cancer publication-title: Eur J Surg Oncol – volume: 34 start-page: 2083 year: 2010 end-page: 2089 article-title: Phase II clinical trial of postoperative S‐1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real‐time RT‐PCR publication-title: World J Surg – year: 2010 – volume: 13 start-page: 276 year: 2013 end-page: 280 article-title: The role of mesothelin in tumor progression and targeted therapy publication-title: Anticancer Agents Med Chem – volume: 21 start-page: 641 year: 2017 end-page: 648 article-title: Lysophosphatidic acid is a biomarker for peritoneal carcinomatosis of gastric cancer and correlates with poor prognosis publication-title: Genet Test Mol Biomarkers – volume: 513 start-page: 202 year: 2014 end-page: 209 article-title: Comprehensive molecular characterization of gastric adenocarcinoma publication-title: Nature – volume: 34 start-page: 1659 year: 2015 end-page: 1680 article-title: Tests of calibration and goodness‐of‐fit in the survival setting publication-title: Stat Med – volume: 6 start-page: 133 year: 2016 end-page: 146 article-title: Mesothelin‐targeted cars: Driving T cells to solid tumors publication-title: Cancer Discov – volume: 14 start-page: 305 year: 2016 article-title: The patterns and timing of recurrence after curative resection for gastric cancer in China publication-title: World J Surg Oncol – volume: 279 start-page: 9190 year: 2004 end-page: 9198 article-title: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion publication-title: J Biol Chem – volume: 267 start-page: 105 year: 2018 end-page: 113 article-title: Lauren histologic type is the most important factor associated with pattern of recurrence following resection of gastric adenocarcinoma publication-title: Ann Surg – volume: 64 start-page: 31 year: 1965 end-page: 49 article-title: The two histological main types of gastric carcinoma: Diffuse and so‐called intestinal‐type carcinoma. An attempt at a histo‐clinical classification publication-title: Acta Pathol Microbiol Scand – volume: 20 start-page: 2902 year: 2000 end-page: 2906 article-title: Mesothelin is not required for normal mouse development or reproduction publication-title: Mol Cell Biol – volume: 15 start-page: 361 year: 1996 end-page: 387 article-title: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors publication-title: Stat Med – volume: 15 start-page: 1389 year: 2014 end-page: 1396 article-title: Adjuvant capecitabine plus oxaliplatin for gastric cancer after d2 gastrectomy (classic): 5‐year follow‐up of an open‐label, randomised phase 3 trial publication-title: Lancet Oncol – volume: 107 start-page: 137 year: 2012 end-page: 142 article-title: Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer publication-title: Br J Cancer – volume: 9 year: 2014 article-title: Mesothelin expression in triple negative breast carcinomas correlates significantly with basal‐like phenotype, distant metastases and decreased survival publication-title: PLoS One – volume: 107 start-page: 2576 year: 2006 end-page: 2580 article-title: Outcome of gastric cancer patients after successful gastrectomy: Influence of the type of recurrence and histology on survival publication-title: Cancer – volume: 105 start-page: 195 year: 2012 end-page: 199 article-title: Mesothelin expression correlates with prolonged patient survival in gastric cancer publication-title: J Surg Oncol – volume: 20 start-page: 1020 year: 2014 end-page: 1028 article-title: Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence‐free and overall survival in early‐stage lung adenocarcinoma publication-title: Clin Cancer Res – volume: 21 start-page: 482 year: 2012 ident: 2021122508114463600_onco12951-bib-0026 article-title: Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-11-0993 – volume: 13 start-page: 276 year: 2013 ident: 2021122508114463600_onco12951-bib-0010 article-title: The role of mesothelin in tumor progression and targeted therapy publication-title: Anticancer Agents Med Chem doi: 10.2174/1871520611313020014 – volume: 61 start-page: 92 year: 2005 ident: 2021122508114463600_onco12951-bib-0018 article-title: Survival model predictive accuracy and ROC curves publication-title: Biometrics doi: 10.1111/j.0006-341X.2005.030814.x – volume: 20 start-page: 2902 year: 2000 ident: 2021122508114463600_onco12951-bib-0024 article-title: Mesothelin is not required for normal mouse development or reproduction publication-title: Mol Cell Biol doi: 10.1128/MCB.20.8.2902-2906.2000 – volume: 36 start-page: 6191 year: 2015 ident: 2021122508114463600_onco12951-bib-0006 article-title: Prognostic significance of the recurrence pattern and risk factors for recurrence in patients with proximal gastric cancer who underwent curative gastrectomy publication-title: Tumour Biol doi: 10.1007/s13277-015-3304-7 – volume: 14 start-page: 305 year: 2016 ident: 2021122508114463600_onco12951-bib-0005 article-title: The patterns and timing of recurrence after curative resection for gastric cancer in China publication-title: World J Surg Oncol doi: 10.1186/s12957-016-1042-y – volume: 15 start-page: 1389 year: 2014 ident: 2021122508114463600_onco12951-bib-0004 article-title: Adjuvant capecitabine plus oxaliplatin for gastric cancer after d2 gastrectomy (classic): 5-year follow-up of an open-label, randomised phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70473-5 – volume: 107 start-page: 137 year: 2012 ident: 2021122508114463600_onco12951-bib-0013 article-title: Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer publication-title: Br J Cancer doi: 10.1038/bjc.2012.235 – volume: 105 start-page: 195 year: 2012 ident: 2021122508114463600_onco12951-bib-0015 article-title: Mesothelin expression correlates with prolonged patient survival in gastric cancer publication-title: J Surg Oncol doi: 10.1002/jso.22024 – volume: 74 start-page: 2907 year: 2014 ident: 2021122508114463600_onco12951-bib-0033 article-title: Discovery of mesothelin and exploiting it as a target for immunotherapy publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-14-0337 – volume: 34 start-page: 2083 year: 2010 ident: 2021122508114463600_onco12951-bib-0008 article-title: Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR publication-title: World J Surg doi: 10.1007/s00268-010-0573-6 – volume: 267 start-page: 105 year: 2018 ident: 2021122508114463600_onco12951-bib-0023 article-title: Lauren histologic type is the most important factor associated with pattern of recurrence following resection of gastric adenocarcinoma publication-title: Ann Surg doi: 10.1097/SLA.0000000000002040 – volume: 6 start-page: 28164 year: 2015 ident: 2021122508114463600_onco12951-bib-0032 article-title: Functional genomic mrna profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types publication-title: Oncotarget doi: 10.18632/oncotarget.4461 – volume: 3 start-page: 63 year: 2000 ident: 2021122508114463600_onco12951-bib-0030 article-title: Role of MMP-7 in the formation of peritoneal dissemination in gastric cancer publication-title: Gastric Cancer doi: 10.1007/PL00011698 – volume: 15 start-page: 361 year: 1996 ident: 2021122508114463600_onco12951-bib-0017 article-title: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors publication-title: Stat Med doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 – volume: 34 start-page: 1659 year: 2015 ident: 2021122508114463600_onco12951-bib-0019 article-title: Tests of calibration and goodness-of-fit in the survival setting publication-title: Stat Med doi: 10.1002/sim.6428 – volume: 65 start-page: 87 year: 2015 ident: 2021122508114463600_onco12951-bib-0001 article-title: Global cancer statistics, 2012 publication-title: CA Cancer J Clin doi: 10.3322/caac.21262 – volume: 379 start-page: 315 year: 2012 ident: 2021122508114463600_onco12951-bib-0002 article-title: Adjuvant capecitabine and oxaliplatin for gastric cancer after d2 gastrectomy (classic): A phase 3 open-label, randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(11)61873-4 – volume: 9 year: 2014 ident: 2021122508114463600_onco12951-bib-0027 article-title: Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival publication-title: PLoS One doi: 10.1371/journal.pone.0114900 – volume: 34 issue: suppl 15 year: 2016 ident: 2021122508114463600_onco12951-bib-0014 article-title: Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR) publication-title: J Clin Oncol – volume-title: American Joint Committee on Cancer. AJCC Cancer Staging Manual year: 2010 ident: 2021122508114463600_onco12951-bib-0016 – volume: 36 start-page: 1131 year: 2010 ident: 2021122508114463600_onco12951-bib-0007 article-title: Surgical treatment for peritoneal carcinomatosis from gastric cancer publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2010.09.006 – volume: 64 start-page: 31 year: 1965 ident: 2021122508114463600_onco12951-bib-0020 article-title: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification publication-title: Acta Pathol Microbiol Scand doi: 10.1111/apm.1965.64.1.31 – volume: 20 start-page: 1020 year: 2014 ident: 2021122508114463600_onco12951-bib-0025 article-title: Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-1862 – volume: 3 start-page: 1870 year: 2013 ident: 2021122508114463600_onco12951-bib-0028 article-title: Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation publication-title: Sci Rep doi: 10.1038/srep01870 – volume: 18 start-page: 2478 year: 2012 ident: 2021122508114463600_onco12951-bib-0012 article-title: Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-2614 – volume: 513 start-page: 202 year: 2014 ident: 2021122508114463600_onco12951-bib-0021 article-title: Comprehensive molecular characterization of gastric adenocarcinoma publication-title: Nature doi: 10.1038/nature13480 – volume: 107 start-page: 2576 year: 2006 ident: 2021122508114463600_onco12951-bib-0003 article-title: Outcome of gastric cancer patients after successful gastrectomy: Influence of the type of recurrence and histology on survival publication-title: Cancer doi: 10.1002/cncr.22317 – volume: 22 start-page: 6829 year: 2016 ident: 2021122508114463600_onco12951-bib-0022 article-title: Molecular mechanisms of peritoneal dissemination in gastric cancer publication-title: World J Gastroenterol doi: 10.3748/wjg.v22.i30.6829 – volume: 6 start-page: 133 year: 2016 ident: 2021122508114463600_onco12951-bib-0011 article-title: Mesothelin-targeted cars: Driving T cells to solid tumors publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-15-0583 – volume: 21 start-page: 641 year: 2017 ident: 2021122508114463600_onco12951-bib-0009 article-title: Lysophosphatidic acid is a biomarker for peritoneal carcinomatosis of gastric cancer and correlates with poor prognosis publication-title: Genet Test Mol Biomarkers doi: 10.1089/gtmb.2017.0060 – volume: 279 start-page: 9190 year: 2004 ident: 2021122508114463600_onco12951-bib-0029 article-title: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion publication-title: J Biol Chem doi: 10.1074/jbc.M312372200 – volume: 52 start-page: 181 year: 1992 ident: 2021122508114463600_onco12951-bib-0031 article-title: Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium publication-title: Cancer Res |
SSID | ssj0015932 |
Score | 2.405408 |
Snippet | Background
Mesothelin is overexpressed in many solid tumors, and recent studies have shown that mesothelin expression is associated with poor outcomes in... Mesothelin is overexpressed in many solid tumors, and recent studies have shown that mesothelin expression is associated with poor outcomes in several... This article examines mesothelin expression with a focus on its potential as a predictive biomarker of peritoneal recurrence after curative surgery and its... |
SourceID | unpaywall pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | e1108 |
SubjectTerms | Adult Aged Aged, 80 and over Biomarkers, Tumor - metabolism Female Gastrectomy Gastrointestinal Cancer GPI-Linked Proteins - metabolism Humans Male Mesothelin Middle Aged Peritoneal Neoplasms - metabolism Peritoneal Neoplasms - mortality Peritoneal Neoplasms - secondary Peritoneal recurrence Prediction Prognosis Retrospective Studies Risk Stomach cancer Stomach Neoplasms - metabolism Stomach Neoplasms - mortality Stomach Neoplasms - pathology Stomach Neoplasms - surgery Survival Survival Analysis |
Title | Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1634%2Ftheoncologist.2018-0896 https://www.ncbi.nlm.nih.gov/pubmed/31015316 https://www.proquest.com/docview/2213917491 https://pubmed.ncbi.nlm.nih.gov/PMC6853112 https://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1634/theoncologist.2018-0896 |
UnpaywallVersion | publishedVersion |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1549-490X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0015932 issn: 1549-490X databaseCode: DIK dateStart: 19960101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1549-490X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0015932 issn: 1549-490X databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1549-490X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0015932 issn: 1549-490X databaseCode: RPM dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVASL databaseName: Open Access: Oxford University Press Open Journals customDbUrl: eissn: 1549-490X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0015932 issn: 1549-490X databaseCode: TOX dateStart: 19960101 isFulltext: true titleUrlDefault: https://academic.oup.com/journals/ providerName: Oxford University Press |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9swED_aFLa-7Htr9lE02KuLZdmy9VhCs2aQD0YDGXswsixvZcELSbytY3_87mTH4Ba2MtibjXWyc_md9LN19xPAmwQ5txBGeyIJQi9ETHjIErRHH81sInUROZ3u8USez8N3i2ixBx93tTBUvlc6veZLqjhwahHt5zeKEzd6U7iv8qIe9V3gSxFes8WZjbSXldyHA0mrTz04mE9mpx_qlHvhxdxtpUYaZV6o_EWT_fWHnrpz1w1CejOv8m5VrvTVd71cdrmvm7yG9-HX7mfXOStfTqptdmJ-XlOE_E9-eQD3GtLLTmuUPoQ9Wz6CO-NmWf8xfBvbDVWC4e3Y2Y8mNbdkow3TbLamZjQos6HbG4ghzWYzDBySEcde39OKgatZZGg-qGop8-UVo6RCg4SaIaH-ZNloNGJvNW1TYtiAsL5-AvPh2cXg3Gs2hPAMjsscUWRIL0ckMlTaChlFuTUK_S3iIks0F4lfGDzTNg-4NgrJiMFrvskyniGTEU-hV-KzHQGzcWJI3UwUOXamuEKU8izQmcn9WGVxH-Tur05No5ZOm3YsU3prQq-mHa-m5NWUvNoHvzVc1YIhfzd5vcNSisFNKza6tF-rTRoESNDxnVHxPjyrsdV2irwcZyuO1nEHdW0DEg7vXikvPzsBcYkcDXl2H3iLz9s_a-zgdtv26XQymCKnjPjzf7jbCzjEY1XXfr6E3nZd2VdIArfZMexfTBfHTUj_Bh67Y5c |
linkProvider | Unpaywall |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fa9swED66FLa-dL-77Bca7NXFsmzZeiyhWTNIGsYCGXswsix3ZcELSbytpX9872TH4Ba2MtibjXWyc_lO-mzdfQJ4nyDnFsJoTyRB6IWICQ9Zgvboo5lNpC4ip9M9nsiTWfhxHs134Ou2FobK90qn13xOFQdOLaL9_EZx4kZvCvdlXtSjvgt8KcIbtjizkfaykvdgV9LqUw92Z5Pp0Zc65V54MXdbqZFGmRcqf95kf_2hp-7cdYuQ3s6rfFCVS33xSy8WXe7rJq_hQ7ja_uw6Z-X7YbXJDs3lDUXI_-SXR7DfkF52VKP0MezY8gncHzfL-k_h59iuqRIMb8eOfzepuSUbrZlm0xU1o0GZDd3eQAxpNpti4JCMOPb6iVYMXM0iQ_NBVUuZLy4YJRUaJNQMCfWZZaPRiH3QtE2JYQPC-uoZzIbHnwcnXrMhhGdwXOaIIkN6OSKRodJWyCjKrVHobxEXWaK5SPzC4Jm2ecC1UUhGDF7zTZbxDJmMeA69Ep_tBTAbJ4bUzUSRY2eKK0QpzwKdmdyPVRb3QW7_6tQ0aum0accipbcm9Gra8WpKXk3Jq33wW8NlLRjyd5N3WyylGNy0YqNL-6Nap0GABB3fGRXvw0GNrbZT5OU4W3G0jjuoaxuQcHj3Snn-zQmIS-RoyLP7wFt83v1ZYwe3u7ZPTyeDU-SUEX_5D3d7BXt4rOraz9fQ26wq-wZJ4CZ72wTzNc46Yns |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mesothelin+Expression+Is+a+Predictive+Factor+for+Peritoneal+Recurrence+in+Curatively+Resected+Stage+III+Gastric+Cancer&rft.jtitle=The+oncologist+%28Dayton%2C+Ohio%29&rft.au=Shin%2C+Su-Jin&rft.au=Park%2C+Sejung&rft.au=Kim%2C+Min+Hwan&rft.au=Nam%2C+Chung+Mo&rft.date=2019-11-01&rft.eissn=1549-490X&rft.volume=24&rft.issue=11&rft.spage=e1108&rft_id=info:doi/10.1634%2Ftheoncologist.2018-0896&rft_id=info%3Apmid%2F31015316&rft.externalDocID=31015316 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1083-7159&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1083-7159&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1083-7159&client=summon |